ArticleClinical cardiology2017
Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.
Article in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation.BioMed research international · 2019Trial
- Prospective use of artificial intelligence-enabled electrocardiogram to assist in clinical decision making regarding defibrillator therapy.HeartRhythm case reports · 2025Article
- A predictive model of super response to cardiac resynchronization therapy in short-term period.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Impact of DCM-Causing Genetic Background on Long-Term Response to Cardiac Resynchronization Therapy.JACC. Clinical electrophysiology · 2024Article
- A machine learning method integrating ECG and gated SPECT for cardiac resynchronization therapy decision support.European journal of nuclear medicine and molecular imaging · 2023Article
- Follow-up of CRT-D patients downgraded to CRT-P at the time of generator exchange.Frontiers in cardiovascular medicine · 2023Article
- Clinical and gated SPECT MPI parameters associated with super-response to cardiac resynchronization therapy.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Review
- Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS-QI 33).Journal of arrhythmia · 2020Article
- Mid-term feasibility and safety of downgrade procedure from defibrillator to pacemaker with cardiac resynchronization therapy.International journal of cardiology. Heart & vasculature · 2019Article
- Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center.Journal of geriatric cardiology : JGC · 2019Article
- Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy.Clinical cardiology · 2019Observational
- Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure.Journal of the American College of Cardiology · 2017Article
- Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.Clinical cardiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe level of improvement in left ventricular ejection fraction (LVEF) in super-responders to cardiac resynchronization therapy (CRT) is exceptional. However, the long-term prognosis remains unknown in a large population. HYPOTHESIS: Whether super-responders haven good long-term outcomes.
methodsWe registered 347 patients with primary CRT-D indication. Super-response was defined by LVEF >50% at follow-up echocardiogram. Best-subset regression analysis identified predictors of super-response. Endpoints were major adverse cardiac events (MACE; eg, all-cause mortality or heart failure hospitalization, cardiac death, and appropriate ICD therapy).
resultsFifty-six (16%) patients with LVEF >50% were classified as super-responders. Female sex (OR: 3.06, 95% CI: 1.54-6.05), nonischemic etiology (OR: 2.70, 95% CI: 1.29-5.68), higher LVEF at baseline (OR: 1.07, 95% CI: 1.02-1.13), and wider QRS duration (OR: 1.17, 95% CI: 1.04-1.32) were predictors of super-response. Cumulative incidence of MACE at a median of 5.3 years was 18% in super-responders, 22% in responders, and 51% in nonresponders (P < 0.001). None of super responders died from cardiac death, compared to 9% of responders and 25% of non-responders (P < 0.001). None of super-responders experienced appropriate ICD therapy, compared with 10% of responders and 21% of non-responders (P < 0.001). In super-responders, the adjusted hazard ratio was 0.37 (95% CI: 0.19-0.73) for MACE and 0.44 (95% CI: 0.20-0.95) for total mortality, compared with non-responders.
conclusionsFemale sex, non-ischemic etiology, higher baseline LVEF, and wider QRS duration were independently associated with super-response. Super-response was associated with persistent excellent prognosis regarding survival and appropriate ICD therapy during long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.